Difference between revisions of "Xavier Duportet"
m (a bit more) |
m (t) |
||
| Line 20: | Line 20: | ||
|employment= | |employment= | ||
}} | }} | ||
| − | '''Xavier Duportet''' is a genome architect and founder of Eligo Biotech, a company that combines [[gene editing]] and microbiome modification<ref>https://www.weforum.org/people/xavier-duportet</ref><ref>https://www.genengnews.com/topics/genome-editing/synthetic-biology/more-than-one-way-to-fight-disease-with-synbio-drugs/</ref>. | + | '''Xavier Duportet''' is a genome architect and founder of Eligo Biotech, a company that combines [[gene editing]] and [[microbiome]] modification<ref>https://www.weforum.org/people/xavier-duportet</ref><ref>https://www.genengnews.com/topics/genome-editing/synthetic-biology/more-than-one-way-to-fight-disease-with-synbio-drugs/</ref>. |
He was selected a [[WEF/Young Global Leaders 2015|Young Global Leader]] by the [[World Economic Forum]] in 2018. | He was selected a [[WEF/Young Global Leaders 2015|Young Global Leader]] by the [[World Economic Forum]] in 2018. | ||
Latest revision as of 05:22, 23 May 2024
 Xavier Duportet      (scientist) | |
|---|---|
 | |
| Born | 7 December 1987 |
| Nationality | French |
| Alma mater | INRIA, AgroParisTech, Ohio State University, University of Auckland, Institut Pasteur |
| Member of | Friends of Europe/Young European Leaders/2017, WEF/Young Global Leaders/2018 |
Genome architect and founder of Eligo Biotech | |
Xavier Duportet is a genome architect and founder of Eligo Biotech, a company that combines gene editing and microbiome modification[1][2].
He was selected a Young Global Leader by the World Economic Forum in 2018.
Eligo Bioscience
Eligo is a MIT-Rockefeller University spinoff, backed by investors Khosla Ventures and Seventure Partners. Eligo Bioscience was elected as one of the 30 most innovative companies in the world by the World Economic Forum in 2017.[3]
Eligo Bioscience is researching precision gene editing to the body's (gut) microbiome. By using CRISPR, phage engineering and synthetic biology, Eligo has in trial several products that can reprogram the microbiome in-situ.[4]
The company tries to create genetically engineered “biological nanobots” to combat antibiotic resistance. The nanobots are made of synthesized DNA and protein that allow them to specifically target resistant bacteria "with sniper-like precision", and "perhaps even deployed before a patient knows a defense is needed".[5]
Hello Tomorrow
Duportet is also the founder and president of Hello Tomorrow, a global non-profit organization, operating in 45 countries, which goal is to accelerate the development of deeptech startups that transform disruptive scientific technologies into products or services to solve societal and industrial challenges. Every year, the organisation receives more than 5000 startup applications, gathers more than 1000 deeptech founders via more than 100 events with leaders such as Michael Bloomberg, Emmanuel Macron and many others, and distributes more than $1M in prizes to the most promising early-stage science startups.[6]
References
- ↑ https://www.weforum.org/people/xavier-duportet
- ↑ https://www.genengnews.com/topics/genome-editing/synthetic-biology/more-than-one-way-to-fight-disease-with-synbio-drugs/
- ↑ https://archive.wikiwix.com/cache/?url=http%3A%2F%2Fwidgets.weforum.org%2Ftechpioneers-2017%2F
- ↑ https://www.linkedin.com/in/duportet
- ↑ https://futurism.com/neoscope/lab-grown-synthetic-nanobots-officially-end-antibiotic-resistance
- ↑ https://www.weforum.org/people/xavier-duportet
This page imported content from Wikipedia on 01.01.2022.Wikipedia is not affiliated with Wikispooks. Original page source here
